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Many long non-coding RNAs (lncRNAs) are expressed in cells but only a few have been well
characterized. In these cases, lncRNAs have been shown to be key regulators of several
cellular processes. Therefore, there is a great need to understand the function of more
lncRNAs and their regulation in response to stimuli. Interferon (IFN) is a key molecule in
the cellular antiviral response. IFN binding to its receptor activates transcription of several
IFN-stimulated genes (ISGs) that function as potent antivirals. In addition, several ISGs are
positive or negative regulators of the IFN pathway. This is essential to ensure a strong
antiviral response and a later return of the cell to homeostasis. As the ISGs described to
date are coding genes, we sought to determine whether IFN also regulates the expression
of long non-coding ISGs. To this aim, we used RNA sequencing to analyze the transcrip-
tome of control and HuH7 cells treated with IFNα2. The results show that IFN-treatment
regulates the expression of several unknown non-coding transcripts. We have validated
two lncRNAs upregulated after treatment with different doses of type I IFNα2 in different
cells or with type III IFNλ. These lncRNAs were also induced by influenza and vesicular
stomatitis virus mutants unable to block the IFN response, but not by several wild-type lytic
viruses tested.These lncRNA genes were named lncISG15 and lncBST2 as they are located
close to ISGs ISG15 and BST2, respectively. Interestingly, inhibition experiments showed
that lncBST2 is a positive regulator of BST2.Therefore lncBST2 has been renamed BISPR,
from BST2 IFN-stimulated positive regulator. Our results may have therapeutic implica-
tions as lncBST2/BISPR, but also lncISG15 and their coding neighbors, are increased in
cells infected with hepatitis C virus and in the liver of infected patients.These results allow
us to hypothesize that several lncRNAs could be activated by IFN to control the potency
of the antiviral IFN response.
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INTRODUCTION
The interferon (IFN)-mediated innate immune response provides
a potent defense against pathogens (1). Upon invasion, pathogen-
associated molecular patterns (PAMPs) are detected by specific
receptors in the cells. These can be located on the surface of the
cell, as in the case of Toll-like receptors (TLRs), or intracellu-
larly, as in the case of the retinoic acid-inducible gene I (RIG-I).
PAMP recognition triggers a series of signaling cascades that lead
to the production and secretion of Type I IFN. Type I IFN (IFNα,
IFNβ, and others) binds to IFN receptors present on the surface
of all cell types and activates Janus-activated kinase/signal trans-
ducer and activator of transcription (JAK/STAT) signaling. This
gives rise to the nuclear translocation of the STAT1/STAT2/IRF9
(IFN regulatory factor 9) complex that binds IFN-stimulated
response elements (ISRE) in the promoters of IFN-stimulated
genes (ISGs) and activates their transcription. A similar response
is induced by Type III IFN (IFNλ) upon binding to its receptor
(2, 3). In contrast, Type II IFN or IFNγ, produced by cells of the
immune system, binds to the widely expressed IFNγ receptor (4,
5) leading to nuclear translocation of STAT1 homodimers, which
bind to gamma-activated sequences (GAS) in the promoter of
immunoregulatory genes.
IFN-stimulated genes are antiviral factors, positive regulators
of the IFN pathway (STAT1 and 2 and IRF1) or negative regula-
tors that help IFN-induced cells to return to cellular homeostasis
(SOCS and UPS18) (6–11). Among antiviral genes, there are fac-
tors that function to increase cell sensitivity to PAMPs (OAS and
PKR) or true antiviral effectors that block viral entry (Mx, IFITM,
and TRIM), virus replication, translation and stability (IFIT, OAS,
PKR, and ISG15), or viral release (viperin and tetherin/BST2)
(8). While most IFN-induced factors known to date are proteins,
IFN also activates the expression of several microRNAs that con-
tribute to the antiviral state or to the control of IFN response
(12). Few studies have been performed to address whether IFN
could also regulate expression of long non-coding RNAs (lncR-
NAs) (13–15). In recent years, viral infection has been reported to
be able to induce the expression of cellular lncRNAs. This has been
shown for infection with enterovirus, influenza, HIV, hepatitis B
and C viruses, and the SARS coronavirus (13, 16–23) (Carnero
et al., in preparation). The lncRNA signature found after infection
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should be a mixture of transcripts induced by the virus and tran-
scripts that respond to the cellular antiviral pathways activated by
the infection. In fact, activation of TLRs by PAMPs induces the
expression of several lncRNAs. TLR2 signaling leads to the acti-
vation of lncRNA-COX2, which regulates the expression of genes
related to the immune system (24). Activation of TLR3 results in
increased NEAT1, which increases the expression of genes such
as IL8 (19). TLR4 controls IL1b-eRNA and IL1b-RBT46 lncR-
NAs whose downregulation diminishes IL1b and accumulation
of LPS-induced RNAs (25). Likewise, the LPS-induced inflamma-
tory response is controlled by lnc-IL7R (26). Innate activation also
induces linc1992/THRIL, which controls TNFα and other genes
involved in the immune response (27). In turn, TNFα induces
Lethe, a pseudogene that responds to NFκB and reduces inflam-
mation by inhibiting NFκB DNA binding activity (28). LncRNA
responses are also critical for the functionality of dendritic cells,
CD4+ and CD8+ T-cells (29–32). Thus, NEST lncRNA con-
trols IFNγ locus in CD8+ T-cells leading to decreased Salmonella
enterica pathogenesis (33, 34).
These studies illustrate the interest in identifying novel lncR-
NAs and elucidating their function and regulation. LncRNAs are
thought to be at least as numerous as protein-coding genes, but
only a few are well characterized (35–38). LncRNAs are tran-
scripts similar to mRNAs but with poor coding potential. They are
more cell type-specific, less expressed, and less well conserved than
mRNAs (29, 39). Interestingly, lncRNAs are cell regulators that can
function in cis, co-transcriptionally, or in trans. Some control the
expression of coding genes located in the same genomic region.
Therefore, the genomic location of lncRNAs can provide hints as
to their functionality. They can be sense or antisense (when over-
lapping with one or more exons of another transcript in the same
or in the opposite strand, respectively); intronic (when derived
from an intron of another transcript); divergent or bidirectional
(when they share a promoter with another transcript in the oppo-
site strand and therefore are co-regulated); or intergenic (when
they are independent, located in between two other genes). Several
mechanisms are involved in the regulation of neighboring or anti-
sense genes by lncRNAs. These include transcriptional activation
or interference, recruitment of chromatin modifiers and remodel-
ers, regulation of imprinting, editing, splicing or translation, and
stability (40–44).
To address the issue of whether IFN could also regulate expres-
sion of lncRNAs, which may play key roles in the antiviral response,
we analyzed the transcriptome of cells treated or not with IFNα2
by RNA sequencing (RNASeq). In this analysis, we identified two
lncRNAs upregulated in response to IFN in different cell lines.
Interestingly, these lncRNAs are expressed from positions in the
genome divergent from the well-characterized ISGs ISG15 and
BST2. Therefore, we have called them lncISG15 and lncBST2.
These lncRNAs and their coding counterparts are also induced
in cells infected with mutants of influenza or vesicular stomatitis
viruses (VSV) that fail to block the IFN response. Surprisingly,
they are also induced in culture cells infected with hepatitis C
virus (HCV) and in the liver of patients with HCV infections.
Finally, according to HUGO regulation, we have renamed lncBST2
BISPR, from BST2 IFN-stimulated positive regulator, as we show
that inhibition of lncBST2 expression by RNAi leads to decreased
levels of BST2 mRNA, providing a new layer of regulation of the
IFN response.
MATERIALS AND METHODS
CELLS AND PATIENT SAMPLES
The HuH7 cell line, derived from a human hepatocarcinoma, was
provided by Dr. Chisari’s lab (Scripps Research Institute, La Jolla,
CA, USA). A549 cells, from human non-small cell lung carcinoma,
were kindly provided by Estanislao Nistal (CIMA, University of
Navarra, Spain). Human liver samples with or without HCV infec-
tion were obtained from the Biobank of the University of Navarra
under approval from the Ethics and Scientific Committees. Liver
tissue sections were snap frozen and stored at −80°C. The clin-
ical data from HCV-infected subjects are shown in Table S1 in
Supplementary Material.
CELL CULTURE
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin–streptavidin and maintained at 37°C in a 5% CO2
atmosphere. Twenty-four hours before treatment with IFN, HuH7
and A549 cells were seeded in six-well plates. Then, 0, 5, 50, 250,
1000, or 10000 units/ml of IFNα2 (Sicor Biotech, Lithuania) were
used in a final volume of 2 ml. HuH7 cells were also treated
with 250 ng/ml of IL28B/IFN-λ3 (R&D Systems) in a final vol-
ume of 2 ml. For treatment with ruxolitinib (Selleckchem), cells
were seeded out 24 h before and treated with 0.8µM ruxolitinib
in a final volume of 2 ml. One hour after treatment media were
discarded and replaced by media containing 100 units/ml IFNα.
Cells were harvested for RNA extraction at the indicated times
post-treatment.
CELL TRANSFECTIONS
siRNAs targeting lncBST2/BISPR were designed using iScore
Designer and RNA Scales (45, 46) and purchased from Dhar-
macon. The lncBST2/BISPR siRNAs targeted the sequence
GACUAGUGUGAGCAACAAA. For cell transfection with siR-
NAs, lipofectamine 2000 reagent (Invitrogen) was used accord-
ing to manufacturer’s instructions. Cells were seeded 24 h before
transfection. For each well of a six-well plate, 80 pmoles siRNA
were used. The siRNA was mixed with 50µl OPTIMEM. Fur-
thermore, 6µl lipofectamine were mixed with 250µl OPTIMEM
media and incubated for 5 min. Then, lipofectamine and siRNA
solutions were mixed and incubated for 20–60 min at room tem-
perature. After incubation, half of the volume of the cell media
was discarded and 300, 150, or 75µl of the lipofectamine mixture
were added to each well of 6, 12, or 24-well plates, respectively.
Six hours post-transfection the media from the cells was discarded
and substituted with DMEM media enriched with 10% FBS and
antibiotics.
VIRUS INFECTIONS
Hepatitis C virus JFH-1 was obtained from an initial viral
stock from the genotype 2a JFH-1 plasmid (pJFH-1) previously
described by Wakita et al. (47). The virus was amplified as
described (15). Influenza virus strain A/PR8/34 WT (PR8), a
mutant lacking NS1 (∆NS1), VSV-GFP, and the mutant M51R
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were kindly provided by Estanislao Nistal (CIMA, University of
Navarra, Spain) (48–50), Semliki Forest Virus (SFV) was a gift
from Cristian Smerdou (CIMA, University of Navarra, Spain), and
Adenovirus serotype 5 (Ad5) was amplified as previously described
(48). VSV-eGFP titration was performed in quadruplicates on
A549 cells. The supernatant from infected cells was collected and
1:10 serial dilutions were performed. Cells were seeded 24 h before
infection in 96-well plates and infected with 50µl of each dilution.
Twenty-four hours after infection, GFP expression was visualized
by microscopy and used to determine the titer. Cells were infected
with HCV at a multiplicity of infection (moi) of 0.3, with VSV at
a moi of 5 and with a moi of 10 of Influenza A, ∆NS1, Ad5, and
SFV. In the case of the lytic viruses, we used a moi of 5 or 10 as
this causes cytopathic effects at 24 h (for VSV, influenza and SFV)
or 48 h (for Ad) in HuH7 or A549 cells. After infection, the virus
was removed and fresh medium was added to the cells. Cells were
harvested for RNA extraction at the indicated times post-infection.
CELLULAR FRACTIONATION
Two million HuH7 cells were incubated in 100µl of cytoplasmic
buffer (50 mM Tris HCl pH7.4, 1 mM EDTA, and 1% NP40) for
5 min at 4°C. Then, cells were centrifuged for 5 min at 3000 g and
the supernatant was used to isolate cytoplasmic RNA. The pellet
was washed with cytoplasmic buffer and centrifuged as before. The
supernatant was discarded and the pellet was used to isolate the
nuclear RNA. RNA from nuclear and cytoplasmic fractions was
isolated with MaxWell 16 research system (Promega).
RNA EXTRACTION AND QUANTITATIVE RT-PCR
Human tissue was homogenized using the ULTRA-TURRAX dis-
persing machine (t25 basic IKA-WERKE) (51). Total RNA from
the tissue was extracted in 1 ml TRIZOL (Sigma-Aldrich) and
recommendations of the supplier were followed (52). DNase (Fer-
mentas) treatment was performed to eliminate DNA from the
samples before RT-PCR reactions. RNA was extracted from cells
with the MaxWell 16 research system from Promega following the
manufacturer’s recommendations. RNA concentration was mea-
sured using NanoDrop 1000 Spectrophotometer. The quality of
the RNA was analyzed by Bioanalyzer (Agilent Technologies).
Reverse Transcription (RT) was performed as described (53).
The reaction was performed in the C1000 Touch Thermal Cycler
from Bio-Rad. The samples were incubated at 37°C for 60 min,
then at 95°C for 60 s and then immediately cooled to 4°C. qPCR
was performed in the CFX96 Real-Time system from Bio-Rad
as described (54). The results were analyzed with Bio-Rad CFX-
manager software. GAPDH levels were evaluated in all the cases
as a reference. Only the samples with similar GAPDH amplifica-
tion were analyzed further. The primers used are listed in Table S2
in Supplementary Material and were designed with the Primer3
program1.
HIGH THROUGHPUT SEQUENCING
RNA of excellent quality, as determined by Bioanalyzer (Agilent
Technologies) was treated with the Ribo-Zero rRNA removal kit
1http://frodo.wi.mit.edu
(Epicenter) to deplete from ribosomal RNA. Library preparation
with TruSeq RNA sample preparation kit (Illumina) and sequenc-
ing was performed at the EMBL genomics core facility (Genecore)
in an Illumina HiSeq 2000. Sequences were paired-end, 150 bases
long, and strand specific. RNASeq data are available at the NCBI
Gene Expression Omnibus (GEO) data repository2.
BIOINFORMATIC ANALYSIS
RNA sequencing data analysis was performed using the follow-
ing workflow: (1) the quality of the samples was verified using
FastQC software; (2) the preprocessing of reads was performed by
elimination of contaminant adapter substrings with Scythe and by
quality-based trimming using Sickle; (3) the alignment of reads to
the human genome (hg19) was performed using the Tophat2 map-
per (55); (4) transcript assembly and quantification using FPKM
of genes and transcripts was carried out with Cufflinks 2 (56); (5)
the annotation of the gene locus obtained was performed using
Cuffmerge with Gencode v16 as reference; and (6) differential
expression analysis was performed using Cuffdiff 2 (56). Genes
were selected as differentially expressed using a p-value thresh-
old of 0.01. Further analysis and graphical representations were
performed using an R/Bioconductor (57). Reads from all the dif-
ferentially expressed sequences were visualized in the Integrative
Genomics Viewer (IGV)3 (58, 59) and the sequences were com-
pared to the ENSEMBL and ENCODE databases and searched for
in the Genome Browser from UCSC4 for more information (60,
61). Candidates were divided into coding, non-coding (according
to UCSC classification), or non-assigned, when the transcription
of the sequence had not been annotated in the databases. Func-
tional enrichment analysis of Gene Ontology (GO) categories was
carried out using a standard hypergeometric test (62). Biological
knowledge extraction was complemented through the use of Inge-
nuity Pathway Analysis (Ingenuity Systems)5, with a database that
includes manually curated and fully traceable data derived from
literature sources.
Open reading frame Finder (NCBI) was used to evaluate the
length of all probable open reading frames (ORFs) in lncISG15
and lncBST2/BISPR. Coding potential was assayed with the cod-
ing potential assessment tool (CPAT) (63, 64) and by searching
the LNCipedia database (65) for the presence of our candidates
in the Pride archive (66) or in lists of transcripts associated with
ribosomes (67, 68). Phylogenetic Codon Substitution Frequen-
cies (PhyloCSF) were also used to predict the coding potential of
lncISG15 and lncBST2/BISPR (69).
STATISTICAL ANALYSIS
Statistical analysis of the RNASeq data has been already described.
Remaining analysis was performed using graph-path. Statistical
significance of infected versus non-infected samples was calculated
using a two-tailed non-parametric Mann–Whitney t -test or with
a two-tailed Students t -test when the samples followed a normal
distribution according to the Shapiro–Wilk test. Welch’s correction
2http://www.ncbi.nlm.nih.gov/geo/
3http://www.broadinstitute.org/igv
4http://genome.ucsc.edu
5http://www.ingenuity.com
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was applied for samples with heterogeneous variance. For correla-
tion studies, a two-tailed non-parametric Spearman analysis was
used. P values lower than 0.05 were deemed as significant.
RESULTS
IDENTIFICATION OF IFNα-REGULATED LncRNAs BY RNASeq
To identify lncRNAs that respond to IFN, we treated HuH7 cells
with 10000 units/ml of IFNα2 for 3 days. These conditions serve
to induce the expression of well-known ISGs such as GBP1,
IRF1, BST2, OAS, or ISG15 (15). In addition, this treatment
induces an antiviral effect, as HCV-infected HuH7 cells treated
with 10000 units/ml of IFNα2, show decreased levels of viral pro-
teins and viral genomes compared to untreated infected cells (data
not shown). Finally, the RNA isolated from HuH7 cells treated
with 10000 units/ml of IFNα2 for 3 days was used to hybridize an
Agilent array. Analysis of the array showed that well-characterized
ISGs such as Mx1, STAT1, IRF9, ISG15, BST2, and several mem-
bers of the GBP, OAS, and IFI families were upregulated with a
very high statistical significance (B> 7) (15). Ingenuity analysis
of the data showed that IFN signaling was the pathway with the
highest enrichment followed by other antiviral responses.
The microarrays were used to identify lncRNAs regulated by
IFNα (15). However, an array will only evaluate the expression
levels of the transcripts that hybridize to probes spotted in the
array. In the case of the lncRNAs, the array used only addresses
the expression of 7419 regions described as long intergenic non-
coding RNAs (lincRNAs). However, it has been estimated that
there could be as many lncRNA genes as coding genes, and some
authors consider that the number of lncRNAs could be as high as
~200000 (37, 38). Therefore, to achieve a more complete identifi-
cation of lncRNAs that respond to IFN, we analyzed the transcrip-
tome by RNASeq. RNA isolated from control cells or HuH7 cells
treated with IFN as described, was sequenced after ribodepletion.
Around 130 million reads were obtained per sample. Analysis was
performed using a bioinformatic workflow that includes Tophat2
and Cufflinks 2 as described in the methods section. The analy-
sis showed that, among the genes upregulated in response to IFN,
there were several ISGs such as Mx1, ISG15, BST2, or members of
the IFI and OAS families (Figure 1A and Table S3 in Supplemen-
tary Material). Ingenuity analysis showed that IFN signaling is a
top canonical pathway (p= 3.3× 10−3), the top upstream regu-
lator is IFNα2 (p= 1.9× 10−8), and cell signaling and infectious
and inflammatory diseases are among the main functions. The
expression of ~1000 coding genes was altered by IFN (Table S3 in
Supplementary Material).
The RNASeq analysis also showed that the expression levels
of many regions that do not correspond to coding genes were
also significantly modified in response to IFN (Figure 1B). Out of
the 890 putative non-coding genes whose expression was signifi-
cantly altered, half were upregulated (Table S3 in Supplementary
Material). All candidates where visualized using IGV (Figure S1
in Supplementary Material) (58, 59). We also paid special atten-
tion to altered sequences located close to well-known ISGs and
to genomic regions that were highly expressed and deregulated in
response to IFN. Eight candidates that fulfill at least one of these
two criteria were chosen for further validation (Table 1 and Figure
S1 in Supplementary Material).
IFN INDUCES THE EXPRESSION OF SEVERAL LncRNAs
To validate the eight candidates chosen, we treated HuH7 cells
with different doses of IFNα2. RNA was isolated from the cells
at 6, 24, 48, or 72 h post-treatment and the expression levels
of the candidates were evaluated by quantitative RT-PCR (qRT-
PCR) (Table 1; Figure 2). All the candidates were induced after
IFN-treatment from 2 to more than 1000-fold. However, many
of the candidates were detected at very low cycles in the PCR
amplification. A closer examination of their sequences indicated
that they contained repetitive sequences or sequences similar to
mitochondrial or ribosomal RNAs that could have led to an erro-
neous alignment of the RNASeq reads to the human genome. We
believe that, even when the oligonucleotides used for amplification
were specific, a partial homology to other sequences could allow
FIGURE 1 | RNASeq analysis of IFN-induced genes. RNA isolated from
HuH7 cells treated for 72 h with 0 or 10000 units/ml of IFNα2, was
sequenced in an Illumina platform. More than 130 million reads per sample
were obtained. Analysis of the sequences resulted in more than 200000
cufflink structures that were divided into coding (A) or non-coding/
non-assigned (B) and positioned in dispersion graphs according to
expression levels. Red dots show cufflink structures significantly
upregulated in IFN-treated samples. Green dots are downregulated
structures. The position of well-known ISGs is indicated (A).
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Table 1 | Characteristics of the lncRNA candidates.
Chr Position Length UCSC Ensembl Validation Ct Rep Seq Features
1 11 85195002–85195217F 216 Intron DLG2 ENSG00000150672 3.6 × 20–21 Yes LSU ribosomal RNA
2 13 110076414–110076761FR 348 No None 3.8 × 8–10 No 99% homology
mitochondrial DNA
3 1 237766286–237766644R 359 miRNA inside ENSG00000198626 5.0 × 5–8 Yes LSU ribosomal RNA
Intron RYR2
4 13 82264067–82264606F 539 ENSG00000214182 1.9 × 29–31 Yes
5 11 77597481–77597691R 211 Intron C11orf67=AAMDC ENSG00000087884 6.9 × 5–7 Yes
Intron INTSA ENSG00000149262
6 9 79186718–79186900R 183 ENSG00000241781 3.7 × 12–14 No LSU ribosomal RNA
7 1 947220–948350 1130 Annotated ENSG00000224969 21.1 × 28–31 No Close to ISG15
8 19 17516503–17529713F 13210 Annotated ENSG00000269640 6530 × 22–31 No Close to BST2
The table indicates for each candidate the chromosome and genomic position, the length of the peaks identified by the sequencing analysis, relevant UCSC infor-
mation, Ensemble gene name, fold-change after IFN-treatment (validation), number of PCR cycles required for detection (Ct), presence of repetitive sequences (rep
seq), and other special features.
FIGURE 2 | lncISG15 and lncBST2/BISPR are induced by IFN. HuH7
cells were treated with 0, 5, 50, 250, 1000, or 10000 units/ml IFNα2 (A) or
with 250 ng/ml IFNλ for the indicated times (B). Then RNA was isolated
from each condition and used to evaluate the expression of lncISG15,
lncBST2/BISPR, ISG15, BST2, and GAPDH mRNAs by qRT-PCR. GAPDH
was used as a reference. The experiments were performed three times
and each value shows the average of three replicas from a representative
experiment. Error bars indicate standard deviations. When significant, the
fold-change of treated versus non-treated cells is indicated at the top of
each bar.
cross-amplification and thus increased possibilities of misleading
results. These candidates were not studied further.
We focused on two lncRNAs with no repetitive sequences whose
expression was highly upregulated in response to IFN (Table 1;
Figure 2). Interestingly, database analysis showed that they are
expressed from positions in the genome located close to ISG15
and BST2, both of which are well-characterized ISGs. This may
have functional relevance as some lncRNAs have been described
to regulate the expression of neighboring genes. Therefore, we
originally named these lncRNAs after their neighbor, lncISG15 and
lncBST2. Later, lncBST2 was renamed BISPR to follow HUGO reg-
ulations. When we evaluated the expression of these lncRNAs and
their neighboring transcripts, we observed that both were strongly
upregulated at early times in response to IFN (Figure 2A). Fur-
thermore, they responded to IFNα2 doses as low as 5 units/ml.
These are similar levels to those found in the sera of some HCV
patients (70). The induction was also observed at late times post-
IFN-treatment. To evaluate further the robustness of the effect
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of IFN on these lncRNAs, we tested whether they also respond to
IFNλ, a type III IFN. HuH7 cells treated with IFNλ for 6, 12, 24, 48,
or 72 h also showed increased levels of lncISG15, lncBST2/BISPR,
and their neighbors (Figure 2B). In this case, all the transcripts
showed a higher upregulation at later times post-IFNλ treatment.
VIRAL INFECTIONS INDUCE THE EXPRESSION OF lncISG15 AND
lncBST2/BISPR
Viruses activate the IFN response by several mechanisms. There-
fore, they have evolved to block IFN production and the activation
of the IFN pathway. The molecular mechanisms involved in this
IFN blockade have been characterized for many viruses. Thus,
for instance, NS1 protein from influenza virus and matrix pro-
tein from VSV are key factors in controlling IFN in infected
cells (48–50, 71). We sought to check whether lncISG15 and
lncBST2/BISPR were induced by the physiological IFN induced
by an influenza virus that lacks NS1. Therefore, we evaluated the
expression of these lncRNAs in cells infected with an influenza
wild-type virus or a NS1 mutant. We also included cells infected
with other RNA viruses such as SFV and HCV or DNA viruses
such as adenovirus. All these viruses have developed mechanisms
to block the cellular antiviral response and, with the exception
of HCV, lead to a lytic infection. Different times post-infection
were evaluated. The last point was collected when the cytopathic
effect was apparent. This occurred at 24 h post-infection in the
case of influenza and SFV or 48 h post-infection, in the case of
adenovirus. HCV-infected cells were collected at 48 and 72 h post-
infection. The results showed that at later times post-infection
with the influenza virus lacking NS1, there was increased expres-
sion of lncISG15, lncBST2/BISPR, and their neighboring cod-
ing transcripts (Figure 3A). This increase was not observed in
cells infected with wild-type influenza virus, or with other wild-
type lytic viruses, suggesting that the induction may be mediated
by IFN.
Most lncRNAs are tissue-specific. To determine whether
lncISG15 and lncBST2/BISPR respond to infection only in HuH7
cells or whether this effect is specific for influenza viruses, we
infected alveolar epithelial A549 cells with VSV-GFP wild-type
virus or with a M51R matrix mutant that fails to control IFN.
We chose A549, because lung cells serve as the primary site for
FIGURE 3 | LncISG15 and lncBST2/BISPR respond to viral infections
in cultured cells. (A) HuH7 cells were mock-treated or infected with
wild-type influenza virus (PR8) or a mutant that lacks NS1 (∆NS1), SFV,
Ad5, or HCV for the indicated times. (B) A549 cells were mock-infected
or infected with VSVM51R for 4, 6, or 10 h. Then, RNA was isolated and
the expression levels of lncISG15, lncBST2/BISPR, ISG15, BST2
(A and B), GBP1 (B), and GAPDH mRNAs were evaluated by qRT-PCR.
GAPDH expression was used as a reference. The experiment was
performed three times. Each value shows the average of three replicas
from a representative experiment. Fold-changes of infected versus
non-infected cells higher than two are indicated. Error bars indicate
standard deviations.
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productive infection of VSV and many respiratory viruses (72).
Infection with the wild-type virus did not increase the expression
of lncBST2/BISPR or BST2 (data not shown). However, A549 cells
infected with the VSV mutant M51R for 4, 6, or 10 h did show
increased levels of lncISG15, lncBST2/BISPR, ISG15, BST2, and
other ISGs such as GBP1 (Figure 3B).
Surprisingly, infection with HCV also increased the expression
of lncISG15, lncBST2/BISPR, and other ISGs, including ISG15,
BST2, and IRF1 (Figure 3A and data not shown). To determine
whether these genes were also upregulated in infected patients, we
used liver samples from HCV-negative and HCV-positive donors.
After quantification of the RNA levels, we observed a significant
increase in lncISG15, lncBST2/BISPR, ISG15, and BST2 in HCV-
infected patients compared to controls (Figure 4A). With the
number of patients evaluated, a significant correlation was not
found between expression levels and infection with a particular
genotype of HCV, presence of HCV-induced hepatocellular carci-
noma (HCC), liver cirrhosis, or with a particular cirrhosis stage.
Therefore, there were no significantly different levels of these tran-
scripts in HCV-infected livers without HCC compared with the
peritumoral tissue of HCV-infected livers with HCC. Although
most of the samples belong to patients that are still alive, no signif-
icant correlation was observed between the levels of the evaluated
transcripts and survival post-diagnosis. Finally, we performed cor-
relation studies to analyze whether in the patients, the expression
level of lncISG15 or lncBST2/BISPR correlates significantly with
the expression level of their neighboring coding genes. The results
show a highly significant positive correlation between lncISG15
and ISG15 or lncBST2/BISPR and BST2 (Figure 4B).
ANALYSIS OF lncISG15 AND lncBST2/BISPR PROMOTERS
The experiments performed so far suggest that a general corre-
lation could exist between the expression of lncISG15 and ISG15
or lncBST2/BISPR and BST2. Each lncRNA and its neighboring
coding gene have similar induction patterns in response to IFN
or to viral infection (compare their levels in Figures 2 and 3).
Furthermore, the levels of each coding/non-coding pair correlate
significantly in patient samples (Figure 4B). To analyze this in
more detail, we performed correlation studies of the coding/non-
coding pairs in all the samples evaluated in Figures 2 and 3. The
results show that the correlation of each pair was highly signif-
icant (Figure S2 in Supplementary Material). This suggests that
they could be co-regulated, and therefore, they could share similar
functions. However, expression of lncISG15 and lncBST2/BISPR
also correlated significantly with the expression of other ISGs such
as OAS, GBP1, or IRF1 (data not shown).
To obtain more information on the relationship between the
coding/non-coding pairs, we searched several databases. LncISG15
and lncBST2/BISPR genes are in head-to-head orientation with
their coding neighbors (Figure S3 in Supplementary Material) and
they could share the same promoter. This is based on the following
facts: (i) the distance between the two genes is<1000 bp, a cut-off
for bidirectional promoters (73, 74); (ii) there is a single DNase
hypersensitivity region located between the genes, and (iii) Poly-
merase II (Pol II) ChipSeq analysis of K562 cells shows a single
peak covering the H3K27Ac region between both genes. Interest-
ingly, the peaks observed for Pol II ChipSeq are increased at 30 min
or 6 h post-treatment with IFNα or IFNγ. Finally, the promoter
regions contain conserved ISRE sites and binding sequences for
IRF1, IRF2, and IRF7.
To discriminate whether lncISG15 and lncBST2/BISPR are
induced directly by the JAK/STAT signaling pathway or by a sec-
ondary wave of the IFN response, we evaluated the expression of
these lncRNAs and their coding neighboring genes in HuH7 or
A549 cells incubated or not with the JAK/STAT inhibitor ruxoli-
tinib. Expression of GBP1, a bona fide ISG, was also evaluated
as a positive control (Figure 5). The results show that the lev-
els of GBP1, BST2, and lncBST2/BISPR are significantly reduced
FIGURE 4 | LncISG15 and lncBST2/BISPR are increased in the liver of
HCV-infected patients. (A) Liver samples from HCV-negative and
HCV-positive donors were used to quantify the levels of lncISG15,
lncBST2/BISPR, ISG15, BST2, and GAPDH mRNAs. Statistical significance
was calculated using a two-tailed non-parametric Mann–Whitney t -test for
lncBST2/BISPR, ISG15, and lncISG15 and with a two-tailed Students t -test
with Welch’s correction for BST2, which follows a normal distribution
according to the Shapiro–Wilk test. (B) Expression levels observed for
lncISG15, lncBST2/BISPR in patient samples were compared to the
expression levels of their coding neighbors ISG15 and BST2, respectively. A
correlation analysis was performed and statistical significance was calculated
using a two-tailed non-parametric Spearman analysis.
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FIGURE 5 | Analysis of the expression of lncISG15, lncBST2/BISPR, and
their coding neighboring genes after inhibition of the JAK/STAT
pathway. HuH7 (A) or A549 (B) cells were mock-treated or incubated with
ruxolitinib for 1 h. Then IFNα was added for 8 h and RNA was isolated to
quantify the expression levels of GBP1, BST2, lncBST2/BISPR, ISG15,
lncISG15, and GAPDH, used as a reference. The experiment was performed
twice in triplicates and the average value is indicated. Error bars indicate
standard deviations. A star denotes statistical significance.
in the presence of ruxolitinib, indicating that their expression is
STAT-dependent. Levels of BST2 and lncBST2/BISPR were also
reduced in cells treated with siRNAs targeting STAT1 or by inhi-
bition of IRF1, a transcription factor that acts downstream of IFN
(data not shown). This indicates that BST2 and lncBST2/BISPR
respond to STATs but also to other transcription factors induced
by IFN. These results agree with the possibility that BST2 and
lncBST2/BISPR share a bidirectional promoter.
In contrast, the effect of the JAK/STAT pathway on ISG15 and
lncISG15 expression was less robust. Treatment with ruxolitinib
decreased the expression of ISG15 and lncISG15, but in the latter,
this effect was only observed in A549 cells. No effect on ISG15
or lncISG15 expression was observed with a milder inhibition of
STAT1 or inhibition of IRF1 using RNA interference (data not
shown). Thus, although ISG15 is induced very rapidly after IFN-
treatment, we do not observe a strong regulation of ISG15 or
lncISG15 by the STAT pathway under the conditions used. In fact,
it has been reported that a major regulator of ISG15 is IRF3, a
transcription factor activated in response to PAMPs, but also a
downstream effector of the IFN response (75).
ANALYSIS OF THE CODING POTENTIAL OF lncISG15 AND
lncBST2/BISPR
We evaluated the coding capacity of lncISG15 and lncBST2/BISPR
bioinformatically. ORF Finder (NCBI) was used to determine all
possible ORFs in these lncRNAs (Figure S4 in Supplementary
Material). The analysis shows that all putative ORFs are shorter
than 50 amino acids. Only two ORFs could be translated according
to their poor susceptibility to nonsense mediated decay. However,
these ORFs have non-consensus Kozak sequences at the initiation
codon and therefore a poor coding capacity. Then,we evaluated the
coding potential of lncISG15 and lncBST2/BISPR with the CPAT
(63, 64) (Figure 6A). CPAT uses a model built with ORF size and
coverage together with codon (Ficket score) and hexamer (hexa-
mer score) usage bias. According to this program, lncISG15 and
lncBST2/BISPR are non-coding as they have a coding probabil-
ity of 0.001 and 0.064, respectively, much lower than 0.364, used
as a threshold with the highest sensitivity and specificity to dif-
ferentiate between coding and non-coding transcripts in humans
FIGURE 6 | lncISG15, lncBST2/BISPR have poor coding potential and
accumulate preferentially in the nucleus. (A) Bioinformatic analysis of
the coding potential of lncISG15 and lncBST2/BISPR. Results obtained from
CPAT and LNCipedia. Two transcripts have been evaluated for
lncBST2/BISPR. lncISG15 and lncBST2/BISPR have a coding probability and
a coding label of “non-coding RNAs” according to these analyses. “Lists”
indicated the number of times that these transcripts have been found in the
pride archive or in lists containing ribosome-associated RNAs published by
Lee or Bazzini. See the text for other details. (B) Subcellular localization of
lncISG15 and lncBST2/BISPR. HuH7 cells were mock-treated or treated
with 10000 units/ml of IFNα2 and divided into nuclear and cytoplasmic
fractions. RNA was isolated from each fraction and used to evaluate the
expression levels of lncISG15 and lncBST2/BISPR by qRT-PCR. MALAT1,
GAPDH, and ISG15 mRNA was also quantified and used as a reference to
calculate the relative levels of each transcript and as a control to evaluate
the subcellular fractionation. The ratio of cytoplasmic to nuclear levels is
shown. The experiment was performed three times and each value shows
the average of three replicas from a representative experiment. Error bars
indicate standard deviations.
(64). LncISG15 and lncBST2/BISPR were also described as non-
coding in LNCipedia (65). This lncRNA database shows that these
lncRNAs are not found in the Pride archive, a database for pro-
teomic data, or in lists of transcripts associated with ribosomes in
ribosome profiling experiments (66–68). Further, lncISG15 and
lncBST2/BISPR were also described as non-coding by the analy-
sis of PhyloCSF, which uses multiple alignments to calculate the
Frontiers in Immunology | Molecular Innate Immunity January 2015 | Volume 5 | Article 655 | 8
Barriocanal et al. lncRNAs regulated by IFN
phylogenetic conservation score and determines whether a multi-
species nucleotide sequence alignment is likely to represent a
protein-coding region (69).
Finally, we evaluated the subcellular localization of lncISG15
and lncBST2/BISPR in HuH7 cells mock-treated or treated with
10000 units/ml of IFNα. RNA was isolated from nuclear or cyto-
plasmic fractions and quantified by qRT-PCR. We found that the
coding GAPDH or ISG15 mRNAs accumulate preferentially in
the cytoplasm while the nuclear RNAs MALAT1 or U6 are prefer-
entially nuclear (Figure 6B data not shown). Similarly, lncISG15
and lncBST2/BISPR, compared to mRNAs, accumulate preferen-
tially in the nucleus. This result, together with the bioinformatic
analyses, strongly suggests that lncISG15 and lncBST2/BISPR are
non-coding RNAs.
LncBST2/BISPR REGULATES THE EXPRESSION OF BST2
To address the role of lncBST2/BISPR, we used RNA interference.
HuH7 cells treated or not with IFN, were transfected with siR-
NAs targeting lncBST2/BISPR and RNA expression was evaluated
by qRT-PCR. The results show that expression of lncBST2/BISPR
was decreased compared to cells transfected with control siRNAs
(Figure 7A). Surprisingly, inhibition of lncBST2/BISPR also led to
decreased levels of BST2 mRNA. Expression of lncISG15, ISG15,
GBP1 or expression of genes located in the genome close to BST2
or lncBST2/BISPR, such as GTPBP3 or MVB12A, was not affected
(Figure 7A and data not shown). To determine whether this
was a general phenomenon, we transfected the siRNAs targeting
lncBST2/BISPR into A549 cells infected or not with the VSV M51R
mutant or treated with IFN. Similarly to what has been observed
in HuH7 cells, the siRNA that targets lncBST2/BISPR leads to
decreased levels of lncBST2/BISPR and BST2 mRNA while the
levels of ISG15 mRNA are not significantly affected (Figure 7B).
Similar results were observed with a different siRNA targeting
lncBST2/BISPR.
DISCUSSION
RNA sequencing analysis of human cells treated with IFNα2 and
controls has allowed the identification of lncRNAs induced in
response to IFN (Figure 1). Analysis of the RNASeq data shows
that several of the upregulated genes are well-known coding ISGs
such as ISG15 or OAS (Figure 1A, Table S3 in Supplementary
Material). Ingenuity analysis confirms the enrichment of genes
involved in the IFN response among the regulated factors. We have
used RNAs from similar IFN-treated and control cells to hybridize
expression arrays (15). Comparison of the datasets obtained in
the analysis of the array and the RNASeq shows that only 13 cod-
ing genes were identified in both studies, including OAS, ISG15,
Mx1, and some members of the IFI family. Generally, overlap
between microarray and RNASeq analysis is not high (76). Fur-
thermore, the overlapping decreases with sequencing depth and
when low fold-changes or low abundance genes are analyzed.
(77). This is because sequencing of low transcript abundances
is characterized by high variance, which impedes their identi-
fication in RNASeq analysis. We believe that this may explain
the poor correlation found between the array and the RNASeq
datasets. In fact, we have determined by qRT-PCR that some IFN-
related low abundance transcripts are detected only in the array
analysis. These are early responders to IFN, which increased only
marginally 3 days after IFN-treatment, when the analysis was per-
formed. Therefore, we believe that some lncRNAs induced early
post-IFN-treatment may have not been identified in our analysis.
Interestingly, in the process of writing this manuscript, a paper
FIGURE 7 | LncBST2 controls the expression of BST2 mRNA. HuH7 (A) or
A549 (B) cells were transfected with control siRNAs (Mock) or siRNAs
targeting lncBST2 for 48 h. HuH7, cells were treated or not with IFNα for 6 h
before RNA isolation (A). A549 cells were infected or not with VSV M51R
(B). Levels of lncBST2, BST2, ISG15, and GAPDH mRNAs were evaluated by
qRT-PCR. The experiments were performed at least three times. Values are
refereed to 100% of the control samples. Error bars indicate standard
deviations from a minimum of three independent experiments.
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was accepted describing the identification of IFN-induced lncR-
NAs by RNASeq in samples treated with IFN for short times (14).
We believe that this study will be complementary to our work.
Together, the datasets should contain lncRNAs regulated at early
and later times post-IFN-treatment. Similarly, the lack of correla-
tion between the microarray and RNAseq datasets also indicates
that they can complement each other.
We have identified two lncRNAs whose expression is highly
upregulated in response to different doses of IFNα (Table 1;
Figure 2A) or IFNλ (Figure 2B). Our results show that induc-
tion of these lncRNAs by IFNα seems faster than that observed for
IFNλ. We cannot rule out the possibility that a fast response to
IFNλmay also be observed when higher doses are used. ENCODE
analysis of polymerase II binding to the promoters of these lncR-
NAs also shows that they may be induced by treatment with IFNα
and IFNγ (Figure S3 in Supplementary Material). These lncRNAs
have been named lncISG15 and lncBST2/BISPR after their neigh-
boring genes, which play a key role in the antiviral IFN response.
Our molecular and bioinformatic analyses strongly suggest that
lncISG15 and lncBST2/BISPR are indeed lncRNAs, as they accu-
mulate preferentially in the nucleus of IFN-treated or untreated
cells (Figure 6B) and they have poor coding potential (Figure 6A
and Figure S4 in Supplementary Material).
In general, the upregulation of lncISG15 and lncBST2/BISPR
mimics that of their coding counterparts (Figures 2–4). In fact,
analysis performed with all the expression data obtained in our
studies, shows a highly significant correlation between lncISG15
and ISG15 and between lncBST2/BISPR and BST2. Significant cor-
relations also exist between these lncRNAs and other IFN-induced
genes such as OAS, GBP1, or IRF1 (Figure S2 in Supplemen-
tary Material and data not shown). This may reflect the fact
that all these genes are induced by IFN with a similar kinetics.
In the case of the lncRNAs and their coding counterparts, cor-
relation of the expression may result from their transcriptional
co-regulation. Experimental and bioinformatic analyses indicate
that BST2 and lncBST2/BISPR are bona fide ISGs strongly induced
by the JAK/STAT pathway in response to IFN (Figure 5 and Figure
S3 in Supplementary Material). Furthermore, expression of BST2,
ISG15, and their neighboring non-coding genes is induced by
downstream effectors of the IFN response. These studies allow
us to suggest that lncISG15/ISG15 and lncBST2/BISPR/BST2 may
share bidirectional promoters. Other IFN-induced gene pairs
may also be co-regulated by bidirectional promoters as these are
enriched in STAT1 binding (78).
Bidirectional promoters often couple genes involved in the
same process, allowing for coordinated temporal and environ-
mental responses (73, 78–82). Non-coding RNAs generated from
bidirectional promoters may have functional roles that affect the
bidirectional promoter, the neighboring protein-coding gene, or
more distal genes (83). These effects could lead to activation or
repression of the expression and could be mediated by either the
transcription process itself or by the produced ncRNA transcript
(84). In this study, we show that post-transcriptional inhibition of
lncBST2/BISPR leads to reduced levels of BST2 mRNA (Figure 7).
Therefore, lncBST2/BISPR should increase transcription or sta-
bility of its coding neighboring gene. Our results demonstrate
that this regulation seems specific for BST2, as lncBST2/BISPR
downregulation does not affect the expression of genes located
nearby, which has been described for compact genomes (85).
Moreover, inhibition of lncBST2/BISPR does not affect expression
levels of other IFN-related genes such as ISG15 or GBP1 (Figure 7
and data not shown).
We anticipate that inhibition of lncBST2/BISPR, and there-
fore of BST2, could impact the antiviral effects of IFN. BST2
is also named tetherin, as it inhibits viral budding by using
anchors that trap virions on the cell membrane (86–88). Several
enveloped viruses have been shown to be susceptible to the action
of BST2/tetherin and have evolved to develop evasion strategies
(87). Interestingly, HIV, influenza, HCV, and VSV are among the
susceptible viruses and could be used to test the antiviral role of
lncBST2/BISPR (49, 89–95). In fact, we show that lncBST2/BISPR
and BST2 are induced after infection with HCV or influenza and
VSV mutant viruses that activate the IFN response (Figure 3).
Upregulation of lncBST2/BISPR, lncISG15, and their coding
neighbors was also observed in patients infected with HCV com-
pared to controls (Figure 4). Similarly, a significant upregulation
of lncBST2/BISPR and ISG15 was also detected in human T-
lymphocytes infected with HIV compared to controls (data not
shown). A non-significant increase in BST2 and lncISG15 was
also observed in these samples. This leads to the possibility that
interference with these factors could have therapeutic relevance. It
is unclear why cells infected by these viruses, which employ several
viral proteins to block the IFN pathway, show activation of these
IFN response genes (96). In the case of HCV, it has been previously
shown that patients with chronic HCV infections express ISGs,
including high levels of ISG15 (97–99). In fact, HCV has evolved
to use some ISGs for viral replication (100, 101). This is the case for
ISG15. ISG15 is an ubiquitin-like protein that attaches to its tar-
gets in a process called ISGylation (102, 103). Protein ISGylation
may result in increased or decreased functionality depending on
the target (104). ISG15 preferentially conjugates newly synthesized
proteins affecting more strongly viral proteins or cellular proteins
translated into IFN-induced cells (105). Viruses such as influenza,
HIV, or VSV are susceptible to the action of ISG15 (103, 106).
In the case of HCV, a pro-HCV role for ISG15 has been reported
(105, 107). ISG15 has been shown to negatively regulate RIG-I and
thus to inhibit the signaling process leading to IFN induction that
affects HCV replication (108). Furthermore, ISG15 expression in
the liver of chronically infected patients is considered a negative
predictive biomarker of the ability of the patients to respond to
IFN therapy (97–99) (Figure 4). In our study, we cannot address
whether lncISG15, BST2, or lncBST2/BISPR are markers for the
susceptibility of HCV patients to respond to IFN-treatment, as the
HCV patients that we have studied are non-responders to IFN.
We believe that, similar to lncBST2/BISPR, lncISG15 could
affect the expression of ISG15 or other genes. This lncRNA-
mediated control has also been described for a lncRNA located
close to the ISG viperin, which has been shown to regulate the
levels of many IFN-inducible genes (14, 109). Further experi-
ments will be required to address the role of lncISG15 and to
decipher the molecular mechanisms that allow the control exerted
by lncBST2/BISPR on BST2. We believe that these studies may be
important to better understand the IFN response and its pro or
antiviral functions on HCV and other viruses.
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